Effectiveness of Topical Huzhang Sanhuang with Standard Nursing for Chemotherapy-Induced Phlebitis: Randomized Controlled Study.

J Vis ExpSep 11, 2026 (epub)
Clinical ResearchOncology (Medical)

Xiaoxiao Zheng, Yajia Ke, Xirong Cheng et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the effectiveness of topical Huzhang Sanhuang (HZSH) combined with standard nursing care in 94 hospitalized patients with chemotherapy-induced phlebitis (CIP). By Day 14, the experimental group showed significantly greater improvement in phlebitis severity (risk ratio for grade ≥ II, 0.42; 95% CI, 0.20-0.87; P = 0.012) compared to the control group receiving magnesium sulfate wet dressing.

Key findings

  • Experimental group had a risk ratio for phlebitis grade ≥ II of 0.42 compared to control.
  • Significant reductions in VAS pain scores were observed in the experimental group (P < 0.01).
  • Levels of hs-CRP and IL-6 were significantly lower in the experimental group (P < 0.01).
  • Faster resolution of local symptoms was noted in the experimental group via Kaplan-Meier analysis.

Why it matters

Chemotherapy-induced phlebitis can significantly impact patient comfort and treatment adherence. Effective management strategies, such as the HZSH formula, may enhance recovery and improve quality of life for affected patients.

Source

PubMed · PMID 42730685

Published in J Vis Exp. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.